Report Description of the APAC OTC Ophthalmology ProductsMarket

Research Scope and Assumption

• The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)


• The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis


• We have used the combination of top-down and bottom-up approaches for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses


• All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis


• Inflation has not been accounted for in order to estimate and forecast the market


• Numbers may not add up due to rounding off

Research Objective:

• To analyze and forecast the market size of APAC OTC Ophthalmology Products market


• To classify and forecast APAC OTC Ophthalmology Products market based on application, drugs, project type, and application.


• To identify drivers and challenges for APAC OTC Ophthalmology Products market


• To examine competitive developments such as mergers and acquisitions, agreements, collaborations, and partnerships, etc., in APAC OTC Ophthalmology Products Drugs market


• To conduct pricing analysis for APAC OTC Ophthalmology Products Drugs market


• To identify and analyze the profile of leading players operating in APAC OTC Ophthalmology Products market

Reason to buy the report:

• Facilitate decision-making based on strong current and forecast data for Renal Cell Carcinoma drug market


• Develop strategies based on the latest regulatory framework


• Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market


• Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the Renal Cell Carcinoma market


• Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders


• To strategically profile key players and comprehensively analyze their market shares and core competencies


• We have technically sound team which do deep dive research and also provide strategy-based consulting analysis

APAC OTC Ophthalmology Products Market Executive Summary

Ophthalmology is a branch of medical science that deals with the structure, function, and various eye diseases. It is used to identify ocular defects or deficiencies and treat eye disorders. Ophthalmic devices are medical equipment designed for diagnosis, surgery, and vision correction. Whereas, the ophthalmic diagnostic devices are gaining increased importance and adoption due to surge in prevalence of various ophthalmic diseases such as glaucoma, cataract, and other vision-related issues in the emerging countries.

Market Size and Key Findings

The APAC OTC Ophthalmology Products market size is at around USD 7.10 billion in 2021 and is projected to reach USD 9.91 billion by 2026, exhibiting a CAGR of 6.9% during the forecast period.

The Asia Pacific is the fastest-growing market. As a result, the ophthalmology products market is expected to witness significant growth during the forecast period. The market growth is attributed to the expanding patient population suffering from vision disorders, advanced medications for treating ophthalmic diseases and improving the healthcare sector The growth contributors in the region are China, India, China, Japan, and Australia.



Market Dynamics

Market Growth Drivers Analysis

The growth of the APAC ophthalmic drugs market is majorly driven by the rising number of individuals suffering from glaucoma and tremendous innovation and funding in developing combination therapies. In addition, the ocular pharmaceuticals market is driven by increased FDA approvals, which raises medication approvals and increases surgeries in the ophthalmology industry due to the high prevalence of reactive defects. In addition, the market is expanding as the population ages, the incidence of eye disorders rises, healthcare spending rises, and the use of minimally invasive surgeries rises.

Market Restraints

the development of new pharmaceuticals is impeded by undesirable side effects and long gestation periods, limiting market expansion. Two issues limit the industry's growth, well-known pharmaceuticals falling off-patent and big players being hampered by the time it takes for new drugs to join the market. In addition, risks associated with ocular disorders and the lack of public understanding of ophthalmology threaten the market.

Competitive Landscape

Key Players

A few promising companies in the Asia-Pacific ophthalmic drugs market profiled in this report are Carl-Zeiss AG, Ellex Medical Lasers Ltd., Hoya Corporation, Novagali Pharma S A. Abbott Medical Optics, Inc., Essilor International SA Other players in the market include insight Vision Inc. Nidek Co.Ltd, Topcon Corporation, and Ziemer Ophthalmic Systems AG

Products in Pipeline

There are currently five molecules in the Pre-registration stage of development that are expected to be granted approval within the forecast period. Two of these are indicted for DES and three for glaucoma. Nearly 36% of the pipeline for glaucoma and DES are molecules in the late stages of development (Phases II and III), and of these, 21 molecules (43%) are indicated for DES and 28 (57%) for glaucoma.

Notable Recent Deals

SUWON, Republic of Korea and CLERMONT-FERRAND, OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, announced a collaboration with Tha Open Innovation, a sister company of Laboratoires Tha S.A.S ("Tha"), the leading independent pharmaceutical company in Europe dedicated to ophthalmology, to develop OliX lead pipeline products OLX301A and OLX301D in Age-related Macular Degeneration (AMD) and subretinal fibrosis along two other ophthalmic pipelines upon exercise of the option. As a part of the collaborative agreement, Tha will have worldwide rights excluding Asia-Pacific for four programs.

Healthcare Policies and Regulatory Landscape

Pricing and Reimbursement scenario of OTC Ophthalmology Products supplements

Many Asian countries are working towards UHC, their plans vary greatly in scope and service provision, with different degrees of out-of-pocket expenditures. Coverage of the latest ophthalmological technologies and procedures is often limited. In the case of Minimally Invasive Glaucoma Surgery (MIGS), for example, availability and reimbursement levels for different technologies varies considerably across the region Moreover, most national reimbursement systems only cover the direct medical costs of surgery and medications. Patients in these countries may still have to cover non-medical costs like travel and lodging, as well as indirect costs from loss of income for the time spent seeking treatment.